<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255993</url>
  </required_header>
  <id_info>
    <org_study_id>SPH3127-102</org_study_id>
    <nct_id>NCT03255993</nct_id>
  </id_info>
  <brief_title>The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People</brief_title>
  <official_title>Multiple Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single center, parallel, randomized, double blind, placebo-controlled phase&#xD;
      Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127&#xD;
      tablet in healthy subjects by increasing multiple dosing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three panels(100mg, 200mg, 400mg), each consisting of eight participants (The number of&#xD;
      individual subjects in each group was not less than 1/3 of the total number).Participants&#xD;
      begin to receive the first dose of SPH3127 100mg. Then Participants begin to receive the&#xD;
      second dose of SPH3127 200mg,after the researchers confirmed that the 100mg dose group was&#xD;
      safe and well tolerated.Then the third dose of SPH3127 400mg must wait for the result of the&#xD;
      second dose's safety and tolerability. If the subjects during escalating dose to the biggest&#xD;
      tolerate dose group were not well tolerated, the study must adjust the maximum dose group and&#xD;
      fall to a low dose group to conduct another test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to assess incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH3127</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma area under curve (AUC)(0-∞) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7; 10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma AUC(0-∞) of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory hematology values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory hematology values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory chemistry values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory chemistry values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory urinalysis values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory urinalysis values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma Cmax of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Maximum time to peak (Tmax) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma Tmax of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate terminal half-life of SPH3127</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>SPH3127 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 50 mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 50mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 100 mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 200mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 100mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 100 mg*4 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 100mg*4 qd *7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 50mg</intervention_name>
    <description>SPH3127 50mg</description>
    <arm_group_label>SPH3127 100mg</arm_group_label>
    <other_name>SPH3127 is a new study drug for hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 100mg</intervention_name>
    <description>SPH3127 100mg</description>
    <arm_group_label>SPH3127 200mg</arm_group_label>
    <arm_group_label>SPH3127 400mg</arm_group_label>
    <other_name>SPH3127 is a new study drug for hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching to SPH3127 50mg</intervention_name>
    <description>Placebo matching to SPH3127 50mg</description>
    <arm_group_label>Placebo to SPH3127 100mg</arm_group_label>
    <other_name>Placebo is oral tablet to matching to SPH3127 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching to SPH3127 100mg</intervention_name>
    <description>Placebo matching to SPH3127 100mg</description>
    <arm_group_label>Placebo to SPH3127 200mg</arm_group_label>
    <arm_group_label>Placebo to SPH3127 400mg</arm_group_label>
    <other_name>Placebo is oral tablet to matching to SPH3127 50mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The body mass index is 18-28kg/m2 (including the critical value), which allows the&#xD;
             minimum weight of men to be 50kg (including the critical value) and 45kg for women&#xD;
             (including the critical value).&#xD;
&#xD;
          2. Before the study,participant has know about the significance , potential benefits,&#xD;
             inconveniences and potential risks of the study&#xD;
&#xD;
          3. Participant has understood the research's procedure and sign the informed consent .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant who are Pregnancy, lactating women, and planned trials begin within six&#xD;
             months of pregnancy&#xD;
&#xD;
          -  Participant who has abnormal Physical examination, laboratory examination results and&#xD;
             clinical significance (such as: liver function examination - aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of&#xD;
             the upper limit of normal)&#xD;
&#xD;
          -  Participant who has a history of cardiovascular, liver, kidney, digestive tract,&#xD;
             nervous system, blood system, familial hematologic disease, abnormal thyroid function,&#xD;
             or mental abnormality&#xD;
&#xD;
          -  Participant who has drug allergy history and anaphylactic reaction&#xD;
&#xD;
          -  Participant who took oral contraceptive in 6 months&#xD;
&#xD;
          -  Participant who used any drug (including Chinese herbal medicine) within 1 week.&#xD;
&#xD;
          -  Participant who donated blood within 2 months&#xD;
&#xD;
          -  Participant who participated clinical trials of any drug in 3 months (as subjects)&#xD;
&#xD;
          -  Participant who has any positive result of virus serology check: human&#xD;
             immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) -&#xD;
             immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and&#xD;
             treponema pallidum antibody (TP)&#xD;
&#xD;
          -  Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug&#xD;
             abuse&#xD;
&#xD;
          -  Participant who the researchers believe that there are volunteers who are not suitable&#xD;
             for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The capital medical university affiliated Beijing anzhen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

